MOR Key Statistics, Chart & Performance
The current stock price of MOR is 18.96 USD. In the past month the price increased by 1.94%. In the past year, price increased by 144.65%.
MOR Latest News, Press Relases and Analysis
MOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About MOR
Company Profile
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Company Info
MorphoSys AG
Semmelweisstr. 7
Planegg BAYERN 82152 DE
CEO: Jean-Paul Kress
Employees: 464
Phone: 4989899270
MorphoSys AG / MOR FAQ
What does MOR do?
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Can you provide the latest stock price for MorphoSys AG?
The current stock price of MOR is 18.96 USD. The price increased by 2.43% in the last trading session.
Does MOR stock pay dividends?
MOR does not pay a dividend.
How is the ChartMill rating for MorphoSys AG?
MOR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy MOR stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MOR.
Can you provide the market cap for MorphoSys AG?
MorphoSys AG (MOR) has a market capitalization of 2.86B USD. This makes MOR a Mid Cap stock.
When does MorphoSys AG (MOR) report earnings?
MorphoSys AG (MOR) will report earnings on 2024-08-29, after the market close.
MOR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MOR. When comparing the yearly performance of all stocks, MOR is one of the better performing stocks in the market, outperforming 98.16% of all stocks.
MOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MOR. MOR may be in some trouble as it scores bad on both profitability and health.
MOR Financial Highlights
Over the last trailing twelve months MOR reported a non-GAAP Earnings per Share(EPS) of -3.38. The EPS decreased by -160.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MOR Forecast & Estimates
12 analysts have analysed MOR and the average price target is 5.06 USD. This implies a price decrease of -73.33% is expected in the next year compared to the current price of 18.96.
For the next year, analysts expect an EPS growth of 20.86% and a revenue growth -3.33% for MOR